A formulation for treating neoplastic diseases, including post-transplant malignancies, genetically-driven neoplasia associated with mTORC1 hyperactivation, and a viral associated malignancy comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. A method of treating neoplastic diseases comprising administering the formulation comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1.

The present invention utilises 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilises novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalised medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparatuses to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

The invention is directed to a pharmaceutical composition that is liquid at 37° C. and 1 atm, comprising a eutectic mixture of at least an active pharmaceutical ingredient (API) salt, a hydrophilic pharmaceutically acceptable eutectic constituent and a polymer solubilizer, and further comprising a precipitation inhibitor (PI). In another aspect, the invention is directed to a method for preparing such a composition.

The present invention relates to an anti-cancer delivery system with a delayed and sustained release of one or more chemotherapeutic agent(s), a mixture for use in the treatment of cancer comprising such a delivery system and a method for producing such a delivery system.

A method of preventing or treating an immunological or inflammatory disease or disorder comprising administering a composition including a combination of rapamycin and metformin, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1; 10:1 to about 4:1; 5:1 to about 3:1; or about 5:1 to about 4:1. The composition may be formulated for oral administration, topical administration, parenteral administration, etc.

A bone graft substitute which combines substantially the high mechanical stability of spherical porous granules without the limitation of reduced intergranular space, and a method for manufacturing the bone graft substitute. In an exemplary embodiment of the invention, the surface of the granules comprises indentations that increases the porosity within the implanted mass significantly and thus provides more space between the granules for tissue ingrowth. The indentations on the granules cause them to have an irregular shape and thus an increase in the intergranular space is achieved, while mechanical stability is maintained. An exemplary method according to the invention includes the steps of manufacturing the granules; mixing the granules with a porogen; pressing the porogen into the surface of at least a portion of the granules; and removing the porogen from the implant mass to form the indentations in the surface where the porogen was pressed into the granules.

Described herein are medical devices and medical implements with high lubricity to flesh (or biological fluid) and/or inhibited nucleation on its surface. The device has a surface comprising an impregnating liquid and a plurality of micro-scale and/or nano-scale solid features spaced sufficiently close to stably contain the impregnating liquid therebetween. The impregnating liquid fills spaces between said solid features, the surface stably contains the impregnating liquid between the solid features, and the impregnating liquid is substantially held in place between the plurality of solid features regardless of orientation of the surface.

A bone graft substitute which combines substantially the high mechanical stability of spherical porous granules without the limitation of reduced intergranular space. The granules have a high porosity whilst maintaining high stability, and can be pushed into a defect without risking significant breakage of the granules and, simultaneously, bone cells can grow into the space between the granules. In an exemplary embodiment of the invention, the surface of the granules comprises indentations, when viewed from the exterior of the granules. An indentation increases the porosity within the implanted mass significantly and thus provides more space between the granules for tissue ingrowth. Due to the indentations on the granules, the granules have an irregular shape and thus an increase in the intergranular space is achieved, while mechanical stability is maintained. A biocompatible polymer, such as a polypeptide, is disposed about at least some of the granules to form a coating thereon.